Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.59 |
| ▸ | MAOB | P27338 | 7/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | F3 | P13726 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | VHL | P40337 | 1/20 | 0.49 |
| ▸ | ELOC | Q15369 | 1/20 | 0.49 |
| ▸ | ELOB | Q15370 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998628 | 1.00 | MAOA (0.59) | MAOAMAOBCYP2A6F7PARP1 | |
| SCHEMBL7983259 | 0.96 | MAOA (0.59) | MAOAMAOBCYP2A6F7PARP1 | |
| SCHEMBL29506179 | 0.88 | PBRM1 (0.59) | MAOAMAOBF7PARP1F3 | |
| SCHEMBL1151032 | 0.88 | PBRM1 (0.59) | MAOAMAOBF7PARP1F3 | |
| SCHEMBL1798900 | 0.84 | MAOA (0.67) | MAOAMAOBCYP2A6PRKCIVHL | |
| SCHEMBL17011806 | 0.83 | MAOA (0.56) | MAOAMAOBCYP2A6PRKCIVHL | |
| SCHEMBL27844098 | 0.80 | MAOA (0.49) | MAOAMAOBCYP2A6PRKCIVHL | |
| SCHEMBL27843801 | 0.80 | MAOA (0.49) | MAOAMAOBCYP2A6PRKCIVHL | |
| SCHEMBL5108894 | 0.80 | MAOA (0.61) | MAOAMAOBCYP2A6PRKCIVHL | |
| SCHEMBL5543621 | 0.78 | MAOA (0.55) | MAOAMAOBCYP2A6PRKCIMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-120152713-A | Tricyclic aryl derivatives and compositions and methods thereof | 昂胜医疗科技公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4561562-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| WO-2024208207-A1 | DISUBSTITUTED NAPHTHALENE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 拜西欧斯（北京）生物技术有限公司 | 2024-10-10 | — | — | WO | disclosed |
| CN-118307484-A | Organic electroluminescent compound and organic electroluminescent device comprising the same | 杜邦特种材料韩国有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-110431215-B | Organic electroluminescent compound and organic electroluminescent device comprising the same | 罗门哈斯电子材料韩国有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024026128-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| CN-117222650-A | Pyridine or pyrimido-ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022127827-A1 | KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-114644631-A | KRAS G12C protein mutation inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MAOA 1534/4885MAOB 1691/4885CYP2A6 2278/4885 |
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | MAOA 29/4885MAOB 6/4885CYP2A6 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.